All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
On 27th April 2017, Takeda's Multiple Myeloma (MM) drug Ixazomib (Ninlaro®) received a draft 'no' from the National Institute for Health and Care Excellence (NICE) for use in combination with lenalidomide and dexamethasone, for the treatment of MM patients that have received at least one prior therapy. Currently, ixazomib is licensed by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for this indication, but in practice is often used to treat relapsed and refractory (RR) MM patients who have exhausted other available therapies.
This is disappointing news for England and Wales, as it is unlikely that ixazomib (a highly convenient orally administered drug) will be routinely available on the NHS, limiting treatment options for RRMM patients. NICE have justified this decision on the basis of limited data to indicate that ixazomib is superior to other currently available therapies, that are also more cost effective. NICE argue that the pivotal clinical trial for ixazomib (Phase III TOURMALINE-MM1 trial) is ongoing, and therefore the data is not fully evaluable, particularly in terms of patient subsets that have received two or more treatments. Takeda is keen to work with NICE in order to revoke this decision and to establish more watertight cost-effectiveness calculations.
References
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?